{"transactions":[{"id":1349148,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":false,"shares":450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":93300,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349147,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":93750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349146,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349145,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.02,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349144,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349143,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":true,"shares":450,"price":12.17,"value":5476.5,"ownership":{"direct":true},"balance_after":267433,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349142,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":19191,"price":45.5,"value":873190.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Sale to cover the exercise price of the options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":266983,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349141,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-26","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":12.17,"value":365100.0,"ownership":{"direct":true},"balance_after":286174,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349140,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":103437,"price":46.04,"value":4762239.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Sale to cover the exercise price of the options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":256174,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349139,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":85000,"price":7.8,"value":663000.0,"ownership":{"direct":true},"balance_after":359611,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349138,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":45000,"price":8.02,"value":360900.0,"ownership":{"direct":true},"balance_after":274611,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1349137,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-11-28T00:09:12.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":45000,"price":7.38,"value":332100.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024."}],"balance_after":229611,"source":{"system":"sec-edgar","filing":"0001104659-24-123807","document":"tm2429758-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924123807/tm2429758-2_4seq1.xml","form_type":"4"}},{"id":1612035,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-02-29T01:00:24.000Z","date":"2024-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":4282,"price":29.53,"value":126447.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 12,000 restricted stock units on February 26, 2024."}],"balance_after":183285,"source":{"system":"sec-edgar","filing":"0001104659-24-028886","document":"tm247552-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924028886/tm247552-1_4seq1.xml","form_type":"4"}},{"id":1680656,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-12T01:00:28.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":45000,"derivative":{"exercise_price":7.38,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-24-003435","document":"tm243091-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924003435/tm243091-1_4seq1.xml","form_type":"4"}},{"id":1680655,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-01-12T01:00:28.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":25,"value":125000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 25, 2023."}],"balance_after":187567,"source":{"system":"sec-edgar","filing":"0001104659-24-003435","document":"tm243091-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924003435/tm243091-1_4seq1.xml","form_type":"4"}},{"id":1680654,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-01-12T01:00:28.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":7.38,"value":36900.0,"ownership":{"direct":true},"balance_after":192567,"source":{"system":"sec-edgar","filing":"0001104659-24-003435","document":"tm243091-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924003435/tm243091-1_4seq1.xml","form_type":"4"}},{"id":1687508,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:15:57.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":71500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":71500,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":71500},"source":{"system":"sec-edgar","filing":"0001104659-24-001495","document":"tm241954-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001495/tm241954-7_4seq1.xml","form_type":"4"}},{"id":1687507,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-01-05T01:15:57.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":19250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":187567,"source":{"system":"sec-edgar","filing":"0001104659-24-001495","document":"tm241954-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001495/tm241954-7_4seq1.xml","form_type":"4"}},{"id":1756179,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-23T20:31:12.000Z","date":"2023-10-19","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":50000,"derivative":{"exercise_price":7.38,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-23-110803","document":"tm2328975-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923110803/tm2328975-1_4seq1.xml","form_type":"4"}},{"id":1756178,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-10-23T20:31:12.000Z","date":"2023-10-19","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":7.38,"value":147600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 280 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2023."}],"balance_after":168317,"source":{"system":"sec-edgar","filing":"0001104659-23-110803","document":"tm2328975-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923110803/tm2328975-1_4seq1.xml","form_type":"4"}},{"id":1869417,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-06-02T23:51:55.000Z","date":"2023-05-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":4150,"price":26.07,"value":108190.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":148037,"source":{"system":"sec-edgar","filing":"0001104659-23-067691","document":"tm2317724-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923067691/tm2317724-3_4seq1.xml","form_type":"4"}},{"id":1869416,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-06-02T23:51:55.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents settlement by the Issuer of performance stock units (\"PSUs\") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2023."}],"balance_after":152187,"source":{"system":"sec-edgar","filing":"0001104659-23-067691","document":"tm2317724-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923067691/tm2317724-3_4seq1.xml","form_type":"4"}},{"id":2052251,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T00:56:42.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":123750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":123750,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001104659-23-004730","document":"tm233829-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004730/tm233829-8_4seq1.xml","form_type":"4"}},{"id":2052250,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-01-19T00:56:42.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":20625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1 share acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2022."}],"balance_after":138187,"source":{"system":"sec-edgar","filing":"0001104659-23-004730","document":"tm233829-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004730/tm233829-8_4seq1.xml","form_type":"4"}},{"id":2290245,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-27T01:42:12.000Z","date":"2022-04-26","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests over a four-year period, with 1/4th of the shares subject to the option vesting on January 15, 2020, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":70000,"derivative":{"exercise_price":7.38,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-050560","document":"tm2212815-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922050560/tm2212815-5_4seq1.xml","form_type":"4"}},{"id":2290244,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-04-27T01:42:12.000Z","date":"2022-04-26","kind":"exercise","acquired":true,"shares":40000,"price":7.38,"value":295200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 554 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022."}],"balance_after":117561,"source":{"system":"sec-edgar","filing":"0001104659-22-050560","document":"tm2212815-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922050560/tm2212815-5_4seq1.xml","form_type":"4"}},{"id":2360164,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-03-03T01:40:28.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":649,"price":24.28,"value":15757.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 1,875 vested restricted stock units on February 28, 2022."}],"balance_after":77007,"source":{"system":"sec-edgar","filing":"0001104659-22-029522","document":"tm228264-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922029522/tm228264-3_4seq1.xml","form_type":"4"}},{"id":2388124,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-18T00:24:23.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":28.73,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-22-024838","document":"tm227111-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922024838/tm227111-2_4seq1.xml","form_type":"4"}},{"id":2388123,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-02-18T00:24:23.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 1,169 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021."}],"balance_after":77656,"source":{"system":"sec-edgar","filing":"0001104659-22-024838","document":"tm227111-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922024838/tm227111-2_4seq1.xml","form_type":"4"}},{"id":2829427,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T23:27:48.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":80000,"derivative":{"exercise_price":23.57,"expiration_date":"2031-02-25","underlying":"Common","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-21-014967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014967/doc4.xml","form_type":"4"}},{"id":2829426,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-02-26T23:27:48.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 2,487 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2020 and September 9, 2020."}],"balance_after":63987,"source":{"system":"sec-edgar","filing":"0001209191-21-014967","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014967/doc4.xml","form_type":"4"}},{"id":3241035,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-28T22:44:13.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":85000,"derivative":{"exercise_price":7.8,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-20-014088","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/doc4.xml","form_type":"4"}},{"id":3353948,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Clinical Operations"}}],"security":"Common Stock","published_at":"2019-12-03T23:32:31.000Z","date":"2019-12-03","kind":"purchase","acquired":true,"shares":30000,"price":5.13,"value":153900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $4.99 to $5.24, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2019."}],"balance_after":49500,"source":{"system":"sec-edgar","filing":"0001209191-19-058839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/doc4.xml","form_type":"4"}},{"id":3618644,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Clinical Operations"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-04T23:27:24.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":45000,"derivative":{"exercise_price":8.02,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-015926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/doc4.xml","form_type":"4"}},{"id":3618643,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Clinical Operations"}}],"security":"Common Stock","published_at":"2019-03-04T23:27:24.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-19-015926","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/doc4.xml","form_type":"4"}},{"id":3694485,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":85599,"kind":"person","name":"Gupta Suneel","position":1,"cik":"0001763923","reported_name":"Gupta Suneel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Clinical Operations"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-16T23:42:35.000Z","date":"2019-01-15","kind":"exercise","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":110000,"derivative":{"exercise_price":7.38,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-003994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/doc4.xml","form_type":"4"}}]}